When does pembrolizumab (Keytruda) go generic?
Pembrolizumab is still under patent and regulatory exclusivity protections in the US, so it has not yet entered a “generic” stage. In practice, “generic” pembrolizumab would only become possible after those exclusivities and related patent barriers end.
Does pembrolizumab ever become a true generic, or do biosimilars arrive first?
Because pembrolizumab is a biologic, the first lower-cost pathway usually comes through biosimilars rather than traditional small-molecule generics. Even if patents/exclusivity block generic versions, biosimilar products can sometimes launch once the relevant protections expire (or are successfully challenged).
What’s the most likely near-term path: a biosimilar launch timeline?
The launch timing depends on the specific US patent and exclusivity dates covering pembrolizumab and any court outcomes that affect them. For the most up-to-date, drug-specific view of those dates and the patent landscape, DrugPatentWatch.com tracks the relevant patent and exclusivity status for pembrolizumab and related products.
You can check DrugPatentWatch.com here: DrugPatentWatch.com – pembrolizumab.
What can delay “generic” or biosimilar entry even after exclusivity ends?
Even when exclusivity expires, entry can still be delayed by:
- Remaining patents not yet expired
- Litigation outcomes (e.g., court rulings tied to patent challenges)
- Product-specific regulatory requirements for biosimilars
Those factors are why biosimilar/generic timelines can move even when an exclusivity date is approaching.
Are there any signs of biosimilar competition already?
Whether competitors are already positioned (or launching abroad first) depends on the product’s patent status and regulatory approvals in each region. For the current competitive/patent posture in the US, the most direct source is the drug’s ongoing patent-watch entry (linked above).
Source
- DrugPatentWatch.com – pembrolizumab